Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

Our system is achieved by integrating diffractiondeep learning methods, which allows high-throughput lensless imaging system to display wide rangehigh-resolution images. In addition, the developed extraction chipsprototype were verified to accurately detect the numberproportion of blood cells under low blood demand. Our system shows great potential in point-of-care blood cells monitoring for cancer patients that could reduce infection riskmortality rate, increase efficacy of chemotherapysupport precision medicine.

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

PPARγ is the master regulator of glucose metabolism.15-keto-PGE2 is an endogenous PPARγ ligand whitch is degraded by ZADH1. We found that increasing 15-keto-PGE2 promotes glucose uptake. We identified several ZADH1 inhibitors which could increase 15-keto-PGE2 promote glucose uptake via activating PPARγ. Our results showed that inhibition of ZADH1 is a novel approach to treat type 2 diabes mell